Trial Profile
The effects of Roflumilast on the chemotactic capacity of leukocytes from COPD patients
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Aug 2016
Price :
$35
*
At a glance
- Drugs Roflumilast (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacodynamics
- 21 Jul 2016 Planned initiation date changed from 1 Aug 2016 to 1 Dec 2015.
- 21 Jun 2016 Planned initiation date changed from 1 Dec 2015 to 1 Aug 2016.
- 28 Dec 2015 New trial record